T1	Participants 35 120	previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010)
T2	Participants 482 558	open-label, phase 2/3 study at 202 academic medical centres in 24 countries.
T3	Participants 1279 1344	Between Aug 28, 2013, and Feb 27, 2015, we enrolled 1034 patients
